BridgeBio Pharma BBIO Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's total revenue?
- BridgeBio Pharma (BBIO) reported total revenue of $194.52M in Q1 2026.
- How has BridgeBio Pharma's total revenue changed year-over-year?
- BridgeBio Pharma's total revenue increased by 66.8% year-over-year, from $116.63M to $194.52M.
- What is the long-term trend for BridgeBio Pharma's total revenue?
- Over 4 years (2021 to 2025), BridgeBio Pharma's total revenue has grown at a 63.8% compound annual growth rate (CAGR), from $69.72M to $502.08M.
- What does total revenue mean?
- The total amount of money generated from business operations before any expenses are deducted.
- How do you interpret total revenue?
- An increase indicates successful product commercialization or expansion of licensing partnerships, while a decrease may signal market saturation or pipeline delays.
- How does total revenue compare across companies?
- Standard across all biopharmaceutical companies, though revenue recognition timing can vary based on licensing deal structures.